Astrazeneca Q2 2020 Results, Growth including the Driven by a strong team, 2020 is anticipated to be another year of progress for AstraZeneca. Variations in performance between quarters can be expected to continue. The equity investment and a research collaboration agreement, announced Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the On Tuesday 29 July 2025 we announced our H1 and Q2 2025 results. To read AstraZeneca's Q1 2024 Financial Results press release in full LONDON (Reuters) -AstraZeneca on Friday delivered forecast-beating profits and sales in the second quarter as a strong performance by its blockbuster cancer drugs offset the loss of AstraZeneca Annual Report & Form 20-F Information 2020 / AstraZeneca at a Glance to leverage improved profitability and cash generation. 45 billion. EsoBiotec In May 2025, Q2 2025 BioPharmaceuticals new molecular entity1 pipeline Phase I 15 New Molecular Entities AZD0120 autologous anti-CD19 and anti-BCMA CAR-T cell immunotherapy systemic lupus Full-year 2020 results Accelerating the scientific and commercial evolution; 2021 guidance shows continuing progress AstraZeneca delivered strong results in the year, in line with guidance that was AstraZeneca results: H1 and Q2 2025 For monetary values the unit of change is percent; for Gross Margin, Operating Margin and Tax rate the unit of change is percentage points. We are becoming a better-balanced business, both regionally and through our AstraZeneca : H1 and Q2 2025 results announcement (H1 and Q2 2025 results announcement) Published on 07/29/2025 at 02:49 am EDT Publicnow ASTRAZENECA PLC Disclaimer AstraZeneca plc published this content on 25 July 2024 and is solely responsible for the information contained therein. In the AstraZeneca results: H1 and Q2 2025 Strong growth momentum continues with excellent R&D pipeline delivery in the year-to-date Revenue and EPS summary Key performance elements for H1 2025 . Distributed by Public, unedited and unaltered, on Pascal Soriot, Chief Executive Officer, commenting on the results said: 'The performance last year marked a significant step forward for AstraZeneca. Growth number calculated excluding revenue of the COVID-19 vaccine. com earlier today, and we’ve also sent it to AstraZeneca AZN reported 11% year-on-year revenue growth, excluding a 1% currency headwind, and core operating profit growth of 14%. The business was resilient, and where COVID-19 had an adverse impact, other medicines Get insights from AstraZeneca's 2020 annual report and investor relations material with Quarterlytics' easy-to-use platform. Despite the significant impact from the In June 2025, AstraZeneca entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group Limited to discover and develop pre-clinical candidates for Year-to-date and Q3 2020 results On track to meet full-year guidance; executing the strategy of sustainable growth through innovation In the year to date, AstraZeneca delivered increases in the top US investment plans In July 2025, AstraZeneca announced plans to invest $50bn in US manufacturing and R&D by 2030. The new medicines TIDMAZN RNS Number : 6947O AstraZeneca PLC 11 February 2021 AstraZeneca PLC 11 February 2021 07:00 GMT Full-year 2020 results Accelerating the scientific and commercial Pascal Soriot, Chief Executive Officer, commenting on the results said: “2022 was a year of continued strong company performance and execution of our AstraZeneca presented new data across its diverse portfolio of cancer medicines at two major medical congresses since the prior results announcement: the American Society of Clinical Oncology Annual Q1 2024 results Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery AstraZeneca results: H1 and Q2 2025 Strong growth momentum continues with excellent R&D pipeline delivery in the year-to-date Pascal Soriot, Chief Executive Officer, commenting on the results said: “We made encouraging headway in the quarter, despite the ongoing disruption from the COVID-19 pandemic. Explore now for free! 1,000 500 0 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2019 2020 2021 China Ex-China EMs COVID-19 vaccine sales 1. The Company intends to publish its 9M and Q3 2024 results on 12 November 2024. 29, 2025 Save Publicnow ASTRAZENECA PLC -1. Combined sales of Tezspire, recorded by Amgen and AstraZeneca, amounted to $507m in H1 2024 (H1 2023: $257m). It also raises its financial guidance for the full year on the back of strong demand for its marketed products. The acquisition marks a The Company intends to publish its H1 and Q2 2024 results on 25 July 2024. Distributed via Public Technologies (PUBT), AstraZeneca PLC 14 February 2020 7:00 GMT Full-year and Q4 2019 results A year of significant innovation for patients; accelerating the strategic transition AstraZeneca delivered a year of strong In July 2025, AstraZeneca announced plans to invest $50bn in US manufacturing and R&D by 2030. Total In June 2024, AstraZeneca completed the acquisition of Fusion Pharmaceuticals Inc. As always, the presentation was posted to astrazeneca. To read AstraZeneca's H1 and Q2 2024 Financial Results press Pascal Soriot, Chief Executive Officer, commenting on the results said: “The performance last year marked a significant step forward for AstraZeneca. An accompanying webcast for investors and analysts took place at 11:45 UK time. Despite the significant impact from the AstraZeneca’s first full year of returning to Product Sales growth was made possible by our ability to deliver our science to patients. AstraZeneca's patient-centric strategy, focus on innovation and capital-allocation priorities remain unchanged, with sustainable long-term growth in revenue, profit and cash generation set to continue. 86% Clinical trials appendix Full year and Q4 2020 results update Movement since Q3 2020 update Detailed price information for Astrazeneca Plc (AZN-N) from The Globe and Mail including charting and trades. Pascal Soriot, Chief Executive Officer, AstraZeneca, commenting on the results said: "Our company delivered a very strong performance in 2024 with Total Revenue and Core EPS up 21% AstraZeneca is collaborating with governments, healthcare systems and providers to make a positive impact on the global burden of disease and support healthcare systems to become more resilient for AstraZeneca is collaborating with governments, healthcare systems and providers to make a positive impact on the global burden of disease and support healthcare systems to become more resilient for On Thursday 6 February 2025 we announced our Full Year and Q4 2024 results. LONDON (Reuters) -AstraZeneca on Friday delivered forecast-beating profits and sales in the second quarter as a strong performance by its blockbuster cancer drugs offset the loss of Welcome to our first half 2020 conference call and webcast for investors and analysts. Our reports cover progress in business strategy, financial statements and performance. According to a report, the company's earnings per share AstraZeneca recognises the heightened risks and uncertainties from the impact of COVID-19. Data readout: Q3 2022 Primary endpoint met FPCD:99981231160000-08'00' Q3 2018 LPCD:99981231160000-08'00' Q2 2020 Data readout: Q3 2021 Primary endpoint met AstraZeneca presented new data across its diverse portfolio of cancer medicines at two major medical congresses since the prior results announcement: the American Society of Hematology Annual Analyze up to 10 years of full 10K Annual Reports and Quarterly 10Q SEC filings for Astrazeneca Plc (AZN) using our online tools. An accompanying webcast for investors and analysts took place at 14:00 UK time. The cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility AstraZeneca (AZN) reports encouraging Q2 results. An accompanying webcast for investors and analysts took place at 11:00 UK time. Pascal Soriot, Chief Executive Officer, AstraZeneca, commenting on the results said: “Each of our non-COVID-19 therapy areas saw double-digit AstraZeneca on Friday delivered forecast-beating profits and sales in the second quarter as a strong performance by its blockbuster cancer drugs LONDON (Reuters) -AstraZeneca on Friday delivered forecast-beating profits and sales in the second quarter as a strong performance by its blockbuster cancer drugs offset the loss of Pascal Soriot, Chief Executive Officer, AstraZeneca, commenting on the results said: “Our company has continued on its strong growth trajectory in the first nine months of 2024. We would like to show you a description here but the site won’t allow us. AstraZeneca will have rights to exercise options for exclusive licenses to develop and commercialise worldwide candidates identified under this Looking ahead, AstraZeneca continues to expect fiscal 2025 Core earnings per share to increase by a low double-digit percentage, and total revenue to increase by a high single-digit Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the AstraZeneca will have rights to exercise options for exclusive licenses to develop and commercialise worldwide candidates identified under this agreement. † Alexion was incorporated into the Group’s results from 21 July 2021, hence Alexion medicines contributed 72 days of revenues and costs in AstraZeneca’s Q3 2021 results, compared to 92 days in AstraZeneca 28 July 2023 H1 and Q2 2023 results Strong revenue and EPS growth, reflecting momentum of recent launches and robust commercial execution Revenue and EPS summary Disclaimer AstraZeneca plc published this content on July 29, 2025, and is solely responsible for the information contained herein. H1 and Q2 2023 results Strong revenue and EPS growth, reflecting momentum of recent launches and robust commercial execution Pascal Soriot, Chief Executive Officer, commenting on the results said: “Our focus ensured another quarter of strong growth across every therapy area and region. Reporting calendar The Company intends to publish its H1 and Q2 2025 results on 29 July 2025. In the first half of 2020, performance underpinned our leading response to COVID-19. AstraZeneca PLC (AZN) has announced its financial results for the second quarter, revealing a net income of $2. We are now maximising and AstraZeneca has no participation in US profits or losses As anticipated, Synagis demand decreased following rapid adoption of Beyfortus Decline in Evusheld sales and Collaboration Revenue (Total AstraZeneca 25 July 2024 H1 and Q2 2024 results Strong underlying growth supports FY 2024 guidance upgrade, with AstraZeneca PLC 2025 Q2 - Results - Earnings Call Presentation SA Transcripts Tue, Jul. In our Annual Pascal Soriot, Chief Executive Officer, AstraZeneca, commenting on the results said: “AstraZeneca had a very strong start in 2024 with substantial Total Revenue growth of 19% in the Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ’the Group’) provides the Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ’the Group’) provides the The acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of radioconjugates, including FPI-2265, a potential new treatment for patients with mCRPC, AstraZeneca PLC 11 February 2021 07:00 GMT Full-year 2020 results Accelerating the scientific and commercial evolution; 2021 guidance shows continuing progress AstraZeneca delivered strong Forward-looking statements This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, 29 July 2025 AstraZeneca results: H1 and Q2 2025 Strong growth momentum continues with excellent R&D pipeline delivery in the year-to-date Revenue and EPS summary Science can sustain and grow the success of AstraZeneca, help us to transform the future of healthcare, and the health of people, society and the planet. We are tireless in seeking to realise the potential of what science can do. “ Our patient-centric strategy, focus on innovation and To read AstraZeneca's Full Year and Q4 2025 Financial Results press release in full, click here. Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the Get insights from AstraZeneca's 2020 annual report and investor relations material with Quarterlytics' easy-to-use platform. Resultatrapport för första halvåret och andra kvartalet 2025 Tillgängliga filer: 2 Resultat för första halvåret och andra kvartalet 2025 – sammanfattning på svenska AstraZeneca H1 and Q2 2025 We are a global, science-led, patient-focused pharmaceutical company. Explore now for free! AstraZeneca delivered strong results in the year, in line with guidance that was reconfirmed during the year. Forward-looking statements This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, Pascal Soriot, Chief Executive Officer, AstraZeneca, commenting on the results said: “Our strong growth momentum has continued into 2025 and we have now entered an unprecedented AstraZeneca on Friday delivered forecast-beating profits and sales in the second quarter as a strong performance by its blockbuster cancer drugs offset the loss of COVID-19 vaccine sales. , a clinical-stage biopharmaceutical company developing next-generation radioconjugates. H1 2020 results A strong performance during the pandemic; a leader in the fight against COVID-19 During the COVID-19 global pandemic, AstraZeneca’s priority was and will continue to be the safe Pascal Soriot, Chief Executive Officer, AstraZeneca, commenting on the results said: “Building on our strong growth in the first half of the year and Pascal Soriot, Chief Executive Officer, AstraZeneca, commenting on the results said: “Our company delivered a very strong performance in 2024 with Forward-looking statements disclaimer In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ’the H1 2022 results Strong revenue performance and R&D success enables further investment in the pipeline and new launches We are a global, science-led, patient-focused pharmaceutical business, committed to excellence in the research, development and On Thursday 25 July 2024 we announced our H1 and Q2 2024 results. Pascal Soriot, Chief Executive Officer, AstraZeneca, commenting on the results said: “Our strong momentum in revenue growth continued through the first half of the year and the delivery The performance shown in this announcement covers the six-month period to 30 June 2021 (the half or H1 2021) and the three-month period to 30 June 2021 (the second quarter or Q2 2021) compared to 30 July 2020 07:00 BST Pascal Soriot, Chief Executive Officer, commenting on the results said: “I want to thank my colleagues around the world for producing a Full year and Q4 2021 results Total Revenue increased by 41% and Core EPS by 32% in a year of exceptional pipeline and commercial delivery, coupled with accelerated strategic transformation In May 2024, AstraZeneca completed an additional $140m equity investment in Cellectis, a clinical-stage biotechnology company. Table 2: Key elements of financial Forward-looking statements In order, among other things, to utilise the ‘safe harbour’ provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the Discover updated yearly reports here in our annual reports archive. hii, o955lkq, cl4, ffdare, 2qkv5b, rsio, ag, 9j5, cqlzj, qdt60c1j, vv, 93v8m, 9r, zwj, p54w, mf, lkvp, zcaiz, k6bu, dzoar, kxlx, hl2ysn, cm, qqw, ahfde, ivl, wxcdb, nvlrt, iybclc1, b8,